PHASE 1/2 STUDY: FRONTLINE BRENTUXIMAB VEDOTIN plus AVD IN PEDIATRIC PTS WITH ADVANCED HODGKIN LYMPHOMA

被引：0
|
作者：
Franklin, Anna [1 ]
Zecca, Marco [1 ]
Fagioli, Franca [1 ]
Luisi, Flavio Augusto [1 ]
Song, Gregory [1 ]
Suri, Ajit [1 ]
Leonard, E. Jane [1 ]
Locatelli, Franco [1 ]
机构：
[1] Childrens Hosp Colorado, Aurora, CO USA
来源：
PEDIATRIC BLOOD & CANCER | 2019年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
106
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort
    Bowers, Jackson T.
    Anna, Jacob
    Bair, Steven M.
    Annunzio, Kaitlin
    Epperla, Narendranath
    Pullukkara, Jerrin Joy
    Gaballa, Sameh
    Spinner, Michael A.
    Li, Shuning
    Messmer, Marcus R.
    Nguyen, Joseph
    Ayers, Emily C.
    Wagner, Charlotte B.
    Hu, Boyu
    Di, Mengyang
    Huntington, Scott F.
    Furqan, Fateeha
    Shah, Nirav N.
    Chen, Christina
    Ballard, Hatcher J.
    Hughes, Mitchell E.
    Chong, Elise A.
    Nasta, Sunita D.
    Barta, Stefan K.
    Landsburg, Daniel J.
    Svoboda, Jakub
    BLOOD ADVANCES, 2023, 7 (21) : 6630 - 6638
  • [12] Frontline PET-Directed Therapy with Brentuximab Vedotin Plus AVD Followed By Nivolumab Consolidation in Patients with Limited Stage Hodgkin Lymphoma
    Park, Steven, I
    Ansell, Stephen M.
    Giri, Sharmila
    Svoboda, Jakub
    Smith, Stephen D.
    Feldman, Tatyana
    Budde, Elizabeth L.
    Ness, Andrew J.
    Choi, Yunsik
    Bierman, Philip J.
    Lee, Hun Ju
    BLOOD, 2022, 140 : 1751 - 1752
  • [13] Phase 1 Results from a Phase 1/2 Study to Assess the Safety, Tolerability and Recommended Phase 2 Dose (RP2D) of Brentuximab Vedotin Plus Doxorubicin, Vinblastine and Dacarbazine (A plus AVD) in Pediatric Patients (Pts) with Advanced Stage Newly Diagnosed Classical Hodgkin Lymphoma (cHL)
    Franklin, Anna
    Zecca, Marco
    Fagioli, Franca
    Luisi, Flavio Augusto
    Song, Gregory
    Suri, Ajit
    Leonard, E. Jane
    Locatelli, Franco
    BLOOD, 2018, 132
  • [14] Real World Experience with Sequential Brentuximab Vedotin Plus AVD Chemotherapy As Frontline Therapy for Older Patients with Classical Hodgkin Lymphoma: A Multicenter Retrospective Study
    Perez, Ariel Perez
    Abdel-Razeq, Nayef
    Al Sagheer, Tiba
    Nahas, George
    Sandoval-Sus, Jose
    Alfonso, Manny
    Silva, Carlos
    Kareem, Syeda Saba
    Tobon, Katherine
    Rosenthal, Allison C.
    Ansell, Stephen M.
    Linhares, Yuliya P. L.
    Moustafa, Muhamad Alhaj
    Saeed, Hayder
    BLOOD, 2024, 144 : 1672 - 1673
  • [15] Novel immunotherapeutic approaches for pediatric classical Hodgkin lymphoma: Nivolumab or brentuximab vedotin with the AVD regimen
    Okeleji, Olayinka
    Gibson, Amber
    Nunez, Cesar
    Garcia, Miriam B.
    Roth, Michael
    Cuglievan, Branko
    McCall, David
    PEDIATRIC BLOOD & CANCER, 2024, 71 (08)
  • [16] Sequential Brentuximab Vedotin and AVD for Older Hodgkin Lymphoma Patients: Initial Results From a Phase 2 Multicenter Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (08) : 8 - 9
  • [17] Brentuximab vedotin plus AVD for non-bulky limited stage Hodgkin lymphoma: A phase II trial.
    Abramson, Jeremy S.
    Arnason, Jon E.
    LaCasce, Ann S.
    Redd, Robert
    Barnes, Jeffrey A.
    Sokol, Lubomir
    Joyce, Robin
    Avigan, David
    Neuberg, Donna S.
    Takvorian, Tak
    Hochberg, Ephraim P.
    Bello, Celeste M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [18] Brentuximab Vedotin in Advanced Hodgkin's Lymphoma
    Ansell, Stephen M.
    Radford, John
    Straus, David J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (16): : 1527 - 1528
  • [19] Brentuximab vedotin for advanced Hodgkin's lymphoma
    Fanale, Michelle A.
    LANCET ONCOLOGY, 2017, 18 (12): : 1566 - 1568
  • [20] Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older
    Forero-Torres, Andres
    Holkova, Beata
    Goldschmidt, Jerome
    Chen, Robert
    Olsen, Gregg
    Boccia, Ralph V.
    Bordoni, Rodolfo E.
    Friedberg, Jonathan W.
    Sharman, Jeff P.
    Palanca-Wessels, Maria Corinna
    Wang, Yinghui
    Yasenchak, Christopher A.
    BLOOD, 2015, 126 (26) : 2798 - 2804
12345